Latest news
Loading news…
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes.
ViaCyte on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
ViaCyte was acquired by Vertex Pharmaceuticals in 2022 for $320M.
Total Funding
$235.54M
Funding Rounds
13
Last Funding
Acquisitions
0
Monthly Visits
Contacts
89
About ViaCyte
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- San Diego, California, United States
ViaCyte Funding Rounds
13 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–5 of 13Show
Page 1 / 3
ViaCyte Key People
Vice President Intellectual Property Counsel Diversity & Inclusion Officer
Vice President, Regulatory and Quality
Vice President, Human Resources
Senior Vice President of Business Development and Operations
President and CEO
CTO
Vice President, Head of Clinical Development
89
professional contacts at ViaCyte
Contact execs at ViaCyte →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
FAQs about ViaCyte
People who checked this page also checked these
Browse the full Acquirezy directory.